Research programme: cancer therapies - CytoGenix

Drug Profile

Research programme: cancer therapies - CytoGenix

Alternative Names: Cancer therapies research programme -CytoGenix

Latest Information Update: 02 Jun 2010

Price : $50

At a glance

  • Originator CytoGenix
  • Class Gene therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cancer metastases

Most Recent Events

  • 23 Jan 2004 Cytogenix and Baylor College of Medicine have entered into an agreement to co-develop a ssDNA expression vector administered via aerosol delivery in the US for metastatic lung cancer
  • 23 Jan 2004 Preclinical trials in Cancer metastases in USA (unspecified route)
  • 22 Oct 2003 This programme is available for licensing (http://www.cytogenix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top